Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Post-trial access roll-over study for ribociclib (LEE011)
2024-514891-41-00Phase 4Authorised
- Sponsor
- Novartis
- Start
- Jul 2022
- Modality
- Small Molecules
- Countries
- 19
01
Overview
Phase 4, open-label, single-arm trial of ribociclib in breast cancer, sponsored by Novartis. Primary endpoints: Frequency and severity of adverse events and serious adverse events and Proportion of participants with clinical benefit. Planned start Jul 2022; status: authorised.
02
Drugs
ribociclib
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2024-514891-41-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-514891-41-00.